NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 05/09/24

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter ...

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June PR Newswire CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO...

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...

2024-04-12 16:25:55 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Read the full article on Seek...

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1 , 2024 /PRNewswire/ -- Neur...

2024-03-28 15:02:28 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to ...

2024-03-13 11:06:04 ET More on NeuroBo Pharmaceuticals NeuroBo stock jumps 14% on weight-loss drug update NeuroBo to begin Phase 1 testing of potential Wegovy rival Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...

2024-03-13 08:29:15 ET Read the full article on Seeking Alpha For further details see: KB Financial, BeiGene, Legend Biotech among premarket gainers' pack

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending T...